Hypersensitivity (especially previous Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme) to the active substance, to the principal active metabolite teriflunomide or to any of the excipients used in preparation of Lefno tablet.
Patients with impairment of liver function.
Patients with severe immunodeficiency states e.g. AIDS.
Patients with significantly impaired bone marrow function or significant anaemia, leucopenia, neutropenia or thrombocytopenia due to causes other than rheumatoid or psoriatic arthritis.
Patients with serious infections.
Patients with moderate to severe renal insufficiency, because insufficient clinical experience is available in this patient group.
Patients with severe hypoproteinaemia e.g. in nephrotic syndrome.
Pregnant women, women of childbearing potential who are not using reliable contraception during treatment with leflunomide and thereafter as long as the plasma levels of the active metabolite are above 0.02mg/l. pregnancy must be excluded before start of treatment with leflunomide.
Breast feeding women.